Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

71.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
67 68 Next >
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines. 
Via MarketBeat
Topics Government
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
FDA panel to discuss AstraZeneca's supplemental application for Andexxa amid safety concerns, including thrombosis risks and efficacy limitations. 
Via Benzinga
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
Via The Motley Fool
Earnings Scheduled For November 12, 2024
Via Benzinga
A Closer Look at AstraZeneca's Options Market Dynamics
Via Benzinga
Smart Money Is Betting Big In AZN Options
Via Benzinga
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. 
Via Benzinga
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention. 
Via Benzinga
Topics Government
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks. 
Via Benzinga
Topics Government
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
AstraZeneca just released some encouraging data about its weight loss drug candidates. 
Via The Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
Via Benzinga
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript
AZN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca reports $13.57 billion in Q3 sales, up 18% year-over-year. Announces $3.5B U.S. investment to boost R&D and manufacturing with 1,000 new jobs. 
Via Benzinga
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat
AstraZeneca Chief Executive Pascal Soriot said the company is taking the allegations "very seriously." 
Via Investor's Business Daily
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
From AstraZeneca
Via Business Wire
AstraZeneca’s 9M and Q3 2024 results
From AstraZeneca
Via Business Wire
The Week Kamala Harris Lost (Nov 4-8), These Large Cap Stocks Lost Big
Kamala Harris lost 2024 US election, 10 large-cap stocks performed poorly: Moderna, Honda, Akamai, ADS, AstraZeneca, Pinterest, MercadoLibre, First Solar, POSCO, Floor & Decor 
Via Benzinga
AstraZeneca Q3 Earnings Preview: Will Cancer, Heart Drugs Fuel Continued Growth?
AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong growth driven by its oncology and cardiovascular portfolios. 
Via Benzinga
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps. 
Via Benzinga
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
From AstraZeneca
Via Business Wire
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
Why Is AstraZeneca Stock Sinking On Tuesday?
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock falls around 7% 
Via Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.